Novo Stock Tumbles on Post-Wegovy Growth Plan — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk stock tumbled after the company unveiled an ambitious post-Wegovy growth strategy promising new drugs to boost sales.
- Investors responded with wariness, with doubts persisting about Ozempic even as Novo laid out plans for its next-generation pipeline.
Why it matters: Novo's post-Wegovy growth plan was meant to reassure investors about life beyond the blockbuster drug, but the stock drop shows it didn't land. Doubts persisting about Ozempic indicate the market is skeptical about both the existing franchise and the future pipeline.
Ask SkimNews
